2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1221
    ProTx II
    		Inhibitor 98.34%
    ProTx II is a selective blocker of Nav1.7 sodium channels with an IC50 of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors.
    ProTx II
  • HY-P5160A
    Phlotoxin-1 TFA
    		Inhibitor
    Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting NaV1.7 channel.
    Phlotoxin-1 TFA
  • HY-163855
    KGP-25
    		Inhibitor
    KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting Nav1.8 in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABAA) in the central nervous system (CNS) for general anesthesia.
    KGP-25
  • HY-100379
    Valrocemide
    		Inhibitor 99.42%
    Valrocemide (TV1901) is a promising antiepileptic agent candidate that shows a broad spectrum of anticonvulsant activity.
    Valrocemide
  • HY-158979
    Nav1.8-IN-14
    		Inhibitor
    Nav1.8-IN-14 (compound 20) is a potent and selective Nav1.8 inhibitor. Nav1.8-IN-14 can be used in the study of pain-related diseases.
    Nav1.8-IN-14
  • HY-19366
    Nav1.7-IN-2
    		Inhibitor 98.28%
    Nav1.
    Nav1.7-IN-2
  • HY-105454
    Recainam
    		Inhibitor 98.27%
    Recainam (Wy-42362) is a potent orally active antiarrhythmic agent and a sodium channel inhibitor. Recainam elevates ventricular fibrillation threshold, suppresses induced cardiac dysrhythmias, and may accentuate cardiac tissue refractoriness heterogeneity. Recainam can be used for the research of arrhythmias.
    Recainam
  • HY-172246
    Zilvetrigine
    		Inhibitor 99.68%
    Zilvetrigine is a sodium channel blocker. Zilvetrigine can be used as analgesics.
    Zilvetrigine
  • HY-123414
    GX-936
    		Inhibitor
    GX-936 (PF-05196233), a potent and Nav1.7-subtype selective inhibitor, binds to the activated state of voltage-sensor domain IV (VSD4).
    GX-936
  • HY-119980S
    Fluphenazine-d8
    		Inhibitor 99.12%
    Fluphenazine-d8 is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
    Fluphenazine-d<sub>8</sub>
  • HY-B0495S1
    Lamotrigine-13C,d3
    		Inhibitor 99.91%
    Lamotrigine-13C,d3 is the 13C- and deuterium labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al.
    Lamotrigine-<sup>13</sup>C,d<sub>3</sub>
  • HY-B1798A
    Tocainide hydrochloride
    		Inhibitor 99.49%
    Tocainide hydrochloride is a sodium channel blocker, it blocks the sodium channels in the pain-producing foci in the nerve membranes. Tocainide hydrochloride is a primary amine analog of lidocaine, can be used for the treatment of tinnitus.
    Tocainide hydrochloride
  • HY-B0495S
    Lamotrigine-13C3,d3
    		Inhibitor
    Lamotrigine-13C3,d3 is the 13C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al.
    Lamotrigine-<sup>13</sup>C<sub>3</sub>,d<sub>3</sub>
  • HY-B0185G
    Lidocaine (GMP)
    		Inhibitor
    Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
    Lidocaine (GMP)
  • HY-N2026R
    Propylparaben (Standard)
    		Inhibitor
    Propylparaben (Propyl parahydroxybenzoate) (Standard) is the analytical standard of Propylparaben (HY-N2026). Propylparaben (Propyl parahydroxybenzoate) is an antibacterial preservative that can be produced by plants and bacteria. Propylparaben is an orally active weak estrogen receptor agonist. Propylparaben regulates the PI3K-AKT and JNK signaling pathways, and induces oxidative stress. Propylparaben is commonly used in cosmetics, pharmaceuticals and foods, and can be used in studies related to ovarian aging and myocardial ischemia-reperfusion injury.
    Propylparaben (Standard)
  • HY-138985
    CAY10568
    		Inhibitor 99.9%
    CAY10568 is a compound based on QX-314 (HY-101350). CAY10568 is physically smaller and less hydrophobic than the QX-314. CAY10568 can be used in studies of inflammation and pain perception.
    CAY10568
  • HY-N2026A
    Propylparaben sodium
    		Inhibitor 99.03%
    Propylparaben (Propyl parahydroxybenzoate) sodium is an antibacterial preservative that can be produced by plants and bacteria. Propylparaben sodium is an orally active weak estrogen receptor agonist. Propylparaben sodium regulates the PI3K-AKT and JNK signaling pathways, and induces oxidative stress. Propylparaben sodium is commonly used in cosmetics, pharmaceuticals and foods, and can be used in studies related to ovarian aging and myocardial ischemia-reperfusion injury.
    Propylparaben sodium
  • HY-B0358AR
    Flunarizine dihydrochloride (Standard)
    		Inhibitor
    Flunarizine (dihydrochloride) (Standard) is the analytical standard of Flunarizine (dihydrochloride). This product is intended for research and analytical applications. Flunarizine dihydrochloride is a potent dual Na+/Ca2+ channel (T-type) blocker. Flunarizine dihydrochloride is a D2 dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects.
    Flunarizine dihydrochloride (Standard)
  • HY-128922S
    Dexamethasone palmitate-d31
    		Inhibitor 99.31%
    Dexamethasone palmitate-d31 is the deuterium labeled Dexamethasone palmitate(HY-128922).Dexamethasone palmitate (DXP) is a proagent of Dexamethasone (HY-14648). Dexamethasone palmitate can be used for the research of inflammation.
    Dexamethasone palmitate-d<sub>31</sub>
  • HY-B0122S
    Topiramate-13C6
    		Inhibitor 99.67%
    Topiramate-13C6 (McN 4853-13C6) is the 13C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate-<sup>13</sup>C<sub>6</sub>
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.